Placebo for Omalizumab

DRUG4 trials

Sponsors

Creighton University, Hugh A Sampson, MD, Stanford University, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Allergic AsthmaFood AllergyHypersensitivityHypersensitivity, FoodMilk AllergyMulti-food AllergyPeanut AllergyPeanut Hypersensitivity

Phase 2

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

CompletedNCT01157117

Hugh A Sampson, MDMilk Allergy

Start: 2010-08-31End: 2015-10-31Updated: 2020-08-14

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

CompletedNCT03679676

Stanford UniversityFood Allergy, Hypersensitivity, Hypersensitivity, Food +2

Start: 2020-02-05End: 2025-05-02Updated: 2026-05-29

Phase 3

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

CompletedNCT03881696

National Institute of Allergy and Infectious Diseases (NIAID)Multi-food Allergy, Peanut Allergy

Start: 2019-07-22End: 2025-07-01Updated: 2025-09-10

Phase 4

Effect of Xolair on Airway Hyperresponsiveness

Creighton UniversityAllergic Asthma

Start: 2004-01-31End: 2011-09-30Target: 22Updated: 2011-09-23

Related Papers

Omalizumab reduces anaphylactic reactions and allows food introduction in food‐allergic in children with severe asthma: An observational study

Allergy2024-09-1622 citations

Omalizumab for the Treatment of Multiple Food Allergies

New England Journal of Medicine2024-02-25256 citations

Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.

2020-04-1730 citations